Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23704668 | 0.98 | MAPT (0.44) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL671403 | 0.89 | MAPT (0.39) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL22261402 | 0.86 | MAPT (0.37) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL19020399 | 0.84 | MAPT (0.38) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL1703078 | 0.81 | MAPT (0.39) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL12093594 | 0.78 | LMNA (0.39) | LMNAL3MBTL1ALDH1A1KMT2AALOX5AP | |
| SCHEMBL20161937 | 0.78 | FLT3 (0.35) | L3MBTL1PDPK1PIK3CAALOX5APCYP2D6 | |
| SCHEMBL10256261 | 0.78 | — | — | |
| SCHEMBL26109487 | 0.78 | L3MBTL1 (0.49) | L3MBTL1PIK3CAJAK2JAK1JAK3 | |
| SCHEMBL5199006 | 0.77 | JAK2 (0.35) | L3MBTL1PDPK1PIK3CAALOX5APCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637738-A2 | INHIBITORS OF JAK2 | Llydaw Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119365454-A | Discovery of covalent EGFR inhibitors through cysteine 775 | 丹娜-法伯癌症研究院 | 2025-01-24 | — | — | CN | disclosed |
| WO-2025017116-A1 | PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024137548-A2 | INHIBITORS OF JAK2 | Llydaw Therapeutics, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137548-A2 | INHIBITORS OF JAK2 | Llydaw Therapeutics, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-114292274-B | Pyrrolo [2,3-d ] pyrimidine derivatives as JAK kinase inhibitors, and preparation method and application thereof | 中国药科大学 | 2023-12-19 | — | — | CN | disclosed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023075479-A1 | NOVEL THIENO[2,3-D]PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR AUTOIMMUNE DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2023-05-04 | — | — | WO | disclosed |
| CN-112771032-B | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors | 江苏先声药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022206939-A1 | HETEROCYCLIC COMPOUND SERVING AS FGFR INHIBITOR AND APPLICATION THEREOF | 海南耀臻生物医药科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| CN-102459264-A | Pyrimidine inhibitors of kinase activity | ABBOTT LAB | 2012-05-16 | — | — | CN | disclosed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | MAPT 2310/4885LMNA 2413/4885L3MBTL1 2652/4885 |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | MAPT 3012/4885LMNA 2619/4885L3MBTL1 3423/4885 |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | MAPT 4548/4885LMNA 3892/4885L3MBTL1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.